The androgenic disease of menopause
If there is no symptom, there is
no disease. If there is no disease no curative
treatment is necessary.
Is there a disease behind the word of
menopause ?
Understanding
diseases of aging:
ageless woman
AGELESS WOMAN in short
AMAZON: AGELESS
WOMAN
Una mujer sana
produces cada día más andrógenos que
hormonas femeninas
- An Anti Aging Treatment
***
Errors in
menopause treatment.
Treatment of this disease
is done by
mesterolone that replaces testosterone and
dihydrotestosterone when it is necessary (the
deficit being demonstrated by blood tests).
Warning
The concept and pathology of
"menopausal disease" has never been described before. The
reality of this pathological entity is founded:
1. on knowledge of the physiology and hormonal biochemistry
of the female cycle, found in the excellent hormonology
treatises (see: Baulieu E-E. and Kelly Paul A. Hormones,
Hermann publishers, 1990).
2. on clinical experience and detailed biochemical
analyzes that began in 1998 in "postmenopausal" women with
characteristic
symptoms
of "menopausal disease". The initial clinical study was
pursued by an appropriate therapeutic attitude when the
"menopausal disease"
is diagnosed biochemically.
3. on the clinical and
biological study of
women who have been treated with
mesterolone and who have been relieved of their
symptoms.
4. each biological study here concerns the biochemical
and clinical singularity of each woman.
5. The word "menopause" is limited to the cessation of
menstruation. Therefore, "therapeutics of this word" do not
relate to a disease an doesn't need a treatment.
6. Consequently, countless
publications, "double blind studies without medically proven
results, published by highly qualified specialists",
"various treatments", "varied herbs", "explanations and
unfounded treatments", "unnecessary hormonal replacements of
all kinds (HRT) "(HRT
=
Estrogen and Progestin
and their derivatives
that cause disasters - see
warning from the NHI in the USA: Important Warning), "books" using the word "menopause"
(more than 28,000,000 references on google!) are not
concerned with the "menopause disease (Androgenic disease of
menopause)" presented for the
first time before a meeting
of doctors in October 2015 and published in
Approaches
to aging control : 19:17-24,October 2015.
7. The terminology
"menopause disease" corresponds in linguistics to a
terminological use of collocations. The term
Androgenic Disease of Menopause is more convenient.
8. The time has come to place the
family doctor at the center of therapeutics for
"androgenic disease of menopause"
***
The menopause
disease (androgenic disease of menopause).pdf
Octobre 2015.
SEMAL Madrid
G. Debled. The
menopause disease (androgenic
disease of menopause).
Approaches
to aging control : 19:17-24,October
2015
To understand this disease of ageing it is advisable to
establish a precise definition of it. Georges Debled MD.
propounds the following definition:
The menopause disease
(
androgenic disease of menopause)
is
the whole of physiopathological
and psychopathological modifications
brought out by
acute or progressive
stop
of ovarian production
of androgens
after definitive
stop of menstruations.
|
"Menopause disease"
is a collocation.
In corpus
linguistics,
a collocation is
a sequence of words or terms that co-occur more
often than would be expected by chance : "menopause disease"
has a technical signification as it is a disease.
Utilized separately, menopause signifies the "stop of
menstruations" and disease signifies the
"deterioration of health".
CAUSE
The ovaries secrete estradiol, progesterone
and
testosterone.
The cessation of estradiol and progesterone are linked with
the stop of ovulation
and of menstrual
hemorrhages which are
physiological
changes.
The drastic reduction in the secretion of androgens hormones
by the ovaries
(at an age where the production of androgens by the
suprarenal glands is already decreased) is generally not
taken into account and
brings about the
androgenic disease of menopause.
Blood rates of ovarian hormones in woman before menopause.
The ovaries secrete estradiol, progesterone
and
testosterone.
The secretions of these three hormones stop in the
ovaries at the time of the menopause.
The secretory and proliferative cycle controlled by
estradiol and progesterone intended to fertilize ovules does
not exist any more after the “suspension of the menses”. One
can logically wonder which reason would justify a systematic
replacement of these hormones except the fact of wanting to
prolong in time an ovarian cycle become useless in the
absence of ovulation?
The total production of testosterone during a menstrual
cycle is more important in quantity compared with the
production of estradiol.
Consequently one is in right to ask for why estradiol
substitution was proposed in the past by neglecting the
production of testosterone?
The sharp fall of front testosterone secretion at the time
and after the stop of menses is responsible for most of the
disorders caused by the menopause disease.
CONSEQUENCES AND SYMPTOMS
The reduction in androgens’ production causes in woman to
different degree:
·
functional symptoms
: hot flashes, irritability, intestinal distension, swollen
legs.
·
local consequences :
o
sclerosis of bladder neck (chronic cystitis, incontinence,
urgencies)
o
sclerosis of vulva (painful or difficult copulation).
·
general consequences
:
o
lipids’ disorders
o
vascular disorders
o
weakness
o
hyper coagulation
o
venous thrombosis
o
rheumatic problems
o
nervous breakdown
o
cerebral involution
o
Alzheimer’s disease
These consequences are wrongfully allotted to the lack of
estradiol and progesterone (a polluted concept) whereas in
fact they are the consequences of a lack of male hormones (testosterone
for general consequences and
dihydrotestosterone
for local genital involution).
General Symptoms
are the same in man suffering from andropause disease
described for the first time by Georges Debled in 1988. See:
http://www.man.uk.georgesdebled.org/andropause
cause
book.htm
and
http://www.man.uk.georgesdebled.org/andropause
uk.htm
Local Symptoms
resulting from of masculine genitalia involutions are:
·
chronic cystitis, incontinence, urgencies.
(sclerosis of
bladder neck)
·
painful or difficult
copulation ( sclerosis of vulva)
and are consequences
of a lack of dihydrotestosterone production (lack of
testosterone leads to a decreased production of
dihydrotestosterone).
Balanced treatment with male hormones (mesterolone) is
indicated in menopause disease as in andropause disease.
This fact is generally ignored so that the administration of
estradiol (or estrogens) associated or not with progesterone
or progestogens doesn’t constitute the treatment for the
menopause disease
whose I gave the definition (androgens’ deficiencies).
One can even wonder whether the “traditional” treatments of
hormonal replacement therapy (HRT) do not worsen the state
of good health. See
http://www.whi.org
TREATMENT OF IN ANDROGENS’
DEFICIENCIES AND OF MENOPAUSE DISEASE (Dr Georges Debled’s
definition) WITH MESTEROLONE
If there is no symptom, there is
no disease. If there is no disease no curative
treatment is necessary.
Orally administration of mesterolone in amounts between 5
milligrams and 25 milligrams per day constitutes the
specific treatment.
Interest for the pharmaceutical industry
1.
Today
Mesterolone is not prescribed for woman and its prescription
is even exclusive for male patients.
2.
The North American Menopause Society (NAMS) defines
Androgens as:
“a
group of hormones that promote the development and
maintenance of male secondary sex characteristics and
structures. They are produced in smaller quantities in women
and are important in the synthesis of estrogen. They also
play a role in sexual function, muscle mass and strength,
bone density, distribution of fat tissue, energy, and
psychological well-being. With women, the major androgens
are produced in the ovaries and adrenal glands and include
testosterone, androstenedione, and dehydroepiandrosterone
(DHEA). Also available as prescription and nonprescription
therapies,
but not government
approved for use in women”.
Mesterolone administration is prohibited for woman by the
manufacturers because of risks of virilisation as opposed to
what this
description
shows with physiological doses.
Mesterolone
covers all indications for androgens with
women
3.
It is here question to industrialize mesterolone at
very another end that for which it was intended by
manufacturing tablets of 5 and 10 milligrams sectile in two
parts what makes it possible to cover a large range of
therapeutic amounts.
4.
Mesterolone is a hormone prescribed for man to
compensate a lack of production of
androgens. Used for man since 1967 it is henceforth
in the public domain. Its manufacturing technique is known.
No harmfulness was described to date.
5.
Before menopause woman secretes
each day of the
cycle 0.2 milligrams of testosterone = 200 micrograms or
200,000 nanograms or 200,000,000 picograms.
Mesterolone makes it
possible to replace androgens whose production is strongly
decreased in woman with menopause disease.
6. The
indications
relate to all the therapeutic ones containing mesterolone
for woman; that the mesterolone is used
alone
or in partnership with all the pharmaceutical
compositions using estrogens alone or in partnership with
progesterone or progestogens ones.
7. Mesterolone prescription is the right way to treat
premenopausal problems in addition to compositions using
estrogens alone or in partnership with progesterone or
progestogens ones. Mesterolone
balances the
properties of estrogens (prescribed with or without
progestogens)
impairing
and excess of actions o their hormonal targets.
8.
"Traditional" compounding
is not prohibited. However the
interest of the industrialization for women is evident.
Making also dermal patches and pills with long lasting
effects.
Why is mesterolone the treatment for androgen's
deficiencies in woman ?
Mesterolone cannot be aromatized in estradiol (contrary to
testosterone). Its methyl radical
inserted on Carbon 1
of the testosterone confers this property.
At physiological
doses Mesterolone does not influence the secretion of the
pituitary gland so that the secretion of LH is not modified
(contrary to testosterone).
•
Mesterolone prescribed in small amounts adds its
effects to those of testosterone secreted by the organism.
•
With the prescribed physiological pharmacological
amounts doping is impossible and the overdose too.
Mesterolone is prescribed orally in amounts varying between
5 milligrams and ten milligrams per day approximately. A
substitution amount of 25 milligrams per day can be
considered. The secretion of LH by the pituitary gland is
not inhibited (contrary to testosterone).
Mesterolone molecular structure has characteristics of
dihydrotestosterone (DHT) which is directly effective on the
masculine sex organs of women (clitoris,
labia majora
and bladder neck) and on brain tissue (preventing
Alzheimer’s disease) (15).
Mesterolone can be prescribed alone.
To restore balance with the androgens Mesterolone can be
associated with certain compositions containing estradiol
and of progesterone (or progestogens) in cases or these
treatments would justify themselves. Any woman secretes each
day 0.2 milligrams of male hormones. This balance is
essential to the good performance of the hormonal targets.
It is most probably
this lack of balance by default of androgens which
explains the disasters revealed by the “WOMENS' HEALTH
INITIATIVE” in addition to inadequate diagnosis and
treatments whith estradiol and progestogens.
http://www.whi.org
Non-existent risks of virilism with mesterolone
treatment
The treatment of androgen’s deficiency simply consists in
replacing missing secretions of testosterone (and
dihydrotestosterone) thanks to mesterolone
properties. In this
case the woman finds simply her former physiological state
and prevents the disastrous consequences described above.
Mesterolone used in small amounts allows that.
Virilism secondary
to an excessive administration of mesterolone is the
consequence of a doping which must be avoided in all cases.
Virilism doesn’t exist at physiological doses
Androgen's scientific biological deficit - Diagnosis
background
About determination of testosterone
and dihydrotestosterone in serum :
-
The GC-MS (Gaz Chromatography- Mass Spectrometry) is the
most precise method
(Taieb and all,
2003) (8)
-
Direct RIA studies are significant
(ACS 180
from Bayer Diagnostics)
(Davison SL and
all. 2005 )
(9)
-
Androgen glucuronides, instead of testosterone, are
interesting markers of androgenic activity in women
(Labrie F. and
all.2006)
(10).
In the Georges Debled’s study the scientific biological
diagnosis of androgen’s deficiencies is made on the total
“pool” of androgens
(RIA) in men since
40
years and in women since 13
years
concluding that the level of androgens’ daily production
is a key diagnosis (see below).This method led
Georges Debled MD.
to the concept of andropause disease
(which is different from hypogonadism) which treatment is
made with mesterolone (See:
www.man.uk.georgesdebled.org/andropause
uk.htm)
The 10 years’ study on androgens’ deficiencies in women is
founded on RIA analyses made by a reference laboratory
(Liège University, CHU, Liège, Belgium)
The Georges Debled’s androgens’ pool study reflects the
daily production of androgens:
Androgens in serum (RIA)
|
·
Total testosterone
·
Dihydrotestosterone
·
Androstanediol glucuronide
·
(Androsterone glycuronide)
|
·
DHEA
·
DHEA Sulfate
·
Δ4-Androstènedione
|
Metabolites in urine over 24 hours
-
Total 17 ketosteroids
-
Complete Chromatography of 17 ketosteroids
-
Androstanediol glucuronide
|
FSH, LH and estradiol in serum
|
|